Boehringer Ingelheim

Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus

Boehringer Drug Scores in Rare Kidney Disease FSGS

Boehringer Ingelheim Takes Rare Kidney Disease Drug to Phase 3 Despite Puzzling Mid-Stage Data

CMS's Medicare Price Negotiations Start Round Three

Nine Biotech Companies that Could Revolutionize Obesity Treatments

FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug

Hospitals Could Earn More for Buying US-Made Drugs, CMS Proposes

Boehringer Signs €1bn+ Deal for Simcere IBD Candidate

Boehringer Ingelheim Gets an IBD Bispecific From Shanghai-Based Simcere

Mansoor Amiji: Rare Gem and Modern-Day Polymath

Tackling Pulmonary Fibrosis: Boehringer Ingelheim’s New Drug + AI Approach

2025 Novel Small Molecule FDA Drug Approvals

Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M

Smartbax Closes €4.7M First Tranche of Pre-Series A Round